(AIM) AIM ImmunoTech Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(AIM) AIM ImmunoTech Inc. Complete Analysis Pack
Download Your Competitive Advantage
This AIM ImmunoTech Inc. BCG Matrix helps you quickly assess where the company’s products or business units fit across Stars, Cash Cows, Question Marks, and Dogs, supporting strategy, portfolio review, and investment decisions. The content on this page is a real preview of the actual analysis, so you can see the format and depth before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Ampligen in myalgic encephalomyelitis/chronic fatigue syndrome
Ampligen is AIM ImmunoTech Inc.’s lead asset for myalgic encephalomyelitis/chronic fatigue syndrome, a disease with no widely accepted curative therapy and very high unmet need. It is AIM’s clearest Star, but it remains investigational, so value still depends on trial data and regulatory progress. The U.S. ME/CFS market is still underserved, with no approved cure and only symptom-focused care.
Ampligen in post-COVID conditions
Post-COVID conditions remain a large care need, with the WHO estimating about 6% of people with COVID-19 develop long COVID and over 17 million U.S. adults reporting it in 2023. AIM ImmunoTech Inc. lists post-COVID conditions as a use case for Ampligen, so the upside is real, but sales proof is still missing. In BCG terms, this is a Stars-style bet with high growth and unproven share.
Ampligen in pancreatic cancer
Ampligen in pancreatic cancer is a named AIM ImmunoTech Inc. oncology target, but it is still not approved for this use. The market is big and urgent: the American Cancer Society estimated 67,440 new U.S. cases and 51,980 deaths in 2025, underscoring strong unmet need. That makes the Star label only potential today.
Ampligen in non-small cell lung cancer
NSCLC is the main lung-cancer market, making up about 85% of cases, and it is a listed Ampligen target. The pool is large and still clinically active, but AIM ImmunoTech Inc. is early stage here, so share depends on real trial data, not story.
Large, validated oncology market
Ampligen still needs proof
Data must drive uptake
Ampligen in ovarian cancer
Ampligen in ovarian cancer sits in a high-need market, with about 324,000 new cases and 207,000 deaths worldwide in 2022, so ongoing treatment demand is real. The target fits AIM ImmunoTech Inc.’s oncology list, but the program is still clinical, so it has not yet earned Star status in a BCG view. Any upside still depends on proof of efficacy, safety, and later-stage data.
- High unmet need
- Clinical-stage only
- Not a confirmed Star
Ampligen: AIM ImmunoTech’s High-Need, High-Reward Star Candidate
Ampligen is AIM ImmunoTech Inc.’s clearest Star candidate because it targets large, high-need markets like ME/CFS, long COVID, and oncology, but it is still investigational. In 2025, pancreatic cancer is estimated at 67,440 U.S. cases and 51,980 deaths, while long COVID still affects over 17 million U.S. adults. That gives AIM ImmunoTech Inc. growth potential, but only if late-stage data turn into sales.
| Area | 2025/2026 data | BCG view |
|---|---|---|
| ME/CFS | No approved cure | Star potential |
| Long COVID | 17M+ U.S. adults | High growth, unproven |
| Pancreatic cancer | 67,440 cases; 51,980 deaths | Early Star |
What is included in the product
Detailed Word Document
BCG matrix of AIM ImmunoTech Inc. maps its pipeline and core assets into invest, hold, or divest priorities.
Editable Excel File
AIM ImmunoTech Inc. BCG Matrix: clean quadrant view to quickly spot strengths, risks, and capital needs.
Reference Sources
AIM ImmunoTech Inc. Reference Sources provide a credible, traceable basis for key claims, helping investors verify assumptions fast and make better decisions.
Cash Cows
Alferon N Injection
Alferon N Injection is AIM ImmunoTech Inc.'s main approved product and its closest BCG Cash Cow, because it is a purified, naturally derived alpha interferon with established regulatory status. AIM still has little commercial scale: for 2025, the company’s filings showed no material product revenue, so Alferon is more a legacy asset than a true cash generator. That makes it a low-growth, low-share holding that can support the portfolio only if sales or partnering improve.
Genital warts indication
Genital warts remains Alferon N's approved niche use, with FDA clearance dating back to 1989. It sits in a mature, specialty market, so growth is limited, but the indication can still support recurring legacy sales for AIM ImmunoTech Inc. The cash-cow value is steady use, not expansion.
Alpha interferon legacy product
Alferon N is AIM ImmunoTech Inc.’s interferon alfa-2a legacy biologic, first launched in the 1980s, so it is a mature, narrow product rather than a broad platform. Legacy specialty biologics usually need low promotion spend and limited sales support, which helps preserve margin. That makes Alpha interferon more of a cash cow than a growth driver.
Specialty prescription niche
AIM ImmunoTech Inc.’s specialty prescription niche is narrow and highly targeted, so it needs far less scaling capital than a broad pipeline. That makes it look more like a mature Cash Cow than a growth asset: modest commercial reach, limited expansion spend, and no need for heavy infrastructure. In FY2025, its small footprint still points to a low-scale, specialty model.
- Narrow niche, low scaling needs
- Fits Cash Cow profile better
- Specialty sales, not mass market
Existing commercial label
AIM ImmunoTech Inc.'s existing commercial label is its only mature asset, while the rest of the story still sits in the pipeline. That matters because an approved label is the most stable near-term revenue source, even if AIM’s current marketed base is still very small.
- Most mature asset, lowest execution risk.
- Near-term cash flow base, but still limited.
- Pipeline remains the main growth driver.
Alferon N’s Revenue Gap Leaves AIM’s Only Cash Cow Struggling
Alferon N Injection is AIM ImmunoTech Inc.'s only mature product and the closest Cash Cow, but FY2025 filings showed no material product revenue. Its 1989 FDA-cleared genital warts use is a niche, low-growth market, so it can support the company only if sales improve.
| Item | FY2025 | BCG read |
|---|---|---|
| Alferon N | No material revenue | Weak Cash Cow |
| Genital warts | Approved since 1989 | Mature niche |
Full Version Awaits
AIM ImmunoTech Inc. Reference Sources
The AIM ImmunoTech Inc. BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No placeholders, no watermarks, and no demo content—just the complete, professionally formatted file. Once purchased, your full BCG Matrix will be delivered instantly for review, sharing, or presentation.
Dogs
Hemispherx Biopharma legacy brand
AIM ImmunoTech Inc. changed its name from Hemispherx Biopharma in 2019, so the old brand is now a legacy corporate asset. It does not create a direct growth engine on its own, and it adds no new product momentum to the BCG view.
In BCG terms, this is a Dog: low growth, weak strategic pull, and limited standalone value. The brand may still carry historical recognition, but it is not a driver of revenue growth or market share expansion.
Ampligen in HIV
Ampligen in HIV sits in a crowded antiviral field with entrenched therapies, so AIM ImmunoTech Inc. has little visible market share here. AIM lists HIV as one of Ampligen’s investigated uses, but the program has no approved product status. That keeps its BCG profile in Dogs: low share, no clear revenue engine.
Ampligen in Hepatitis B
Ampligen in Hepatitis B sits in a crowded antiviral field, and the category is huge: the WHO estimates about 254 million people live with chronic hepatitis B. AIM ImmunoTech lists hepatitis B only as an exploratory use for Ampligen, with no approved product, no scale, and no clear revenue stream. That fits a Dogs-style, low-share program.
Ampligen in COVID-19
Ampligen in COVID-19 sits in AIM ImmunoTech’s Dogs quadrant: COVID-19 demand has normalized from peak-pandemic levels, and by end-2025 it was not a clear commercial growth engine. AIM still lists COVID-19 among Ampligen’s studied uses, but the market is far smaller than in 2020-2022.
- Peak-pandemic demand has faded
- Studied use, not core revenue driver
- Low growth visibility by end-2025
Dormant legacy programs
AIM ImmunoTech's dormant legacy programs fit the Dog profile because the Company’s disclosed focus stays on just 2 core assets: Ampligen and Alferon N. In a micro-cap biotech, overhead can still drain cash from projects with no commercial traction or clear path to revenue.
- 2 core programs remain the focus
- No commercial traction = Dog-like
- Legacy spend can trap capital
So, any outside program that lacks near-term data, partnering interest, or sales support is a capital drag rather than a growth driver.
AIM ImmunoTech’s Legacy Assets Lack a Clear Revenue Engine
AIM ImmunoTech Inc.’s Dogs are legacy, low-share assets with no approved-product revenue engine. Ampligen’s HIV and hepatitis B uses remain exploratory, and COVID-19 demand has faded from peak-pandemic levels.
| Area | Dog signal |
|---|---|
| Ampligen | No approved sales |
| HIV | Low share |
| Hepatitis B | Exploratory only |
That leaves AIM ImmunoTech Inc. with limited cash-return visibility and weak standalone growth.
Question Marks
Ampligen in renal cancer
Ampligen in renal cancer is a Question Mark for AIM ImmunoTech Inc. because renal cell carcinoma is a large market, with about 434,840 new cases and 155,953 deaths worldwide in 2022, but AIM still has no approved product here. The program needs clear efficacy data and real adoption to move out of speculation. Without that, it risks drifting toward Dog status.
Ampligen in malignant melanoma
Melanoma is a high-value immuno-oncology target: it caused about 330,000 new cases and 58,000 deaths worldwide in 2022. AIM ImmunoTech Inc. lists malignant melanoma among Ampligen’s investigated cancers, but the drug still has no proven commercial share in this indication. So this fits a Question Mark: real upside, but clinical and market risk stay high.
Ampligen in breast cancer
Ampligen in breast cancer is a Question Mark for AIM ImmunoTech: the addressable market is huge, but the program is still unproven. Breast cancer remains one of the biggest oncology categories, with about 2.3 million new cases worldwide each year, so even a small share could matter. Still, without clear clinical and commercial validation, the upside stays speculative.
Ampligen in colorectal cancer
Colorectal cancer is a huge market: GLOBOCAN 2022 estimates 1.9 million new cases and 0.9 million deaths worldwide. AIM ImmunoTech is testing Ampligen in this setting, but it has no proven commercial share yet, so the asset fits a Question Mark in BCG terms.
The upside is real, but so is the risk: large demand does not create share, and Ampligen still needs clinical proof and adoption to matter.
- Large global cancer market
- Ampligen still early
- Share not established
- High upside, high risk
Ampligen in prostate cancer
Ampligen in prostate cancer stays a Question Mark for AIM ImmunoTech Inc.: the market is huge, as prostate cancer was the world’s 2nd most diagnosed cancer in 2022, with about 1.5 million new cases. But Ampligen is still investigational, so it has no proven commercial pull here yet. It needs clear clinical wins and a path to market to move up.
- Large oncology market
- Still investigational
- Needs clinical proof
- Commercial progress lags
AIM ImmunoTech’s Cancer Bets: Big Markets, Still Unproven
AIM ImmunoTech Inc. Ampligen programs in renal, melanoma, breast, colorectal, and prostate cancer are Question Marks: each sits in a large oncology market, but none has proven commercial share or approval yet. That makes the upside real, but the conversion to revenue still depends on clinical wins.
| Indication | Latest market size | Status |
|---|---|---|
| Renal cancer | 434,840 cases, 155,953 deaths | Unproven |
| Melanoma | 330,000 cases, 58,000 deaths | Unproven |
| Breast cancer | 2.3M cases | Unproven |
| Colorectal cancer | 1.9M cases, 0.9M deaths | Unproven |
| Prostate cancer | 1.5M cases | Unproven |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.